KemPharm (KMPH) Receiving Somewhat Favorable News Coverage, Analysis Shows

News articles about KemPharm (NASDAQ:KMPH) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. KemPharm earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 44.7336497692714 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of research firms have issued reports on KMPH. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. Finally, Canaccord Genuity reissued a “buy” rating and set a $7.00 price target on shares of KemPharm in a research report on Monday, September 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. KemPharm presently has an average rating of “Buy” and a consensus price target of $8.05.

Shares of KemPharm (KMPH) opened at $3.80 on Monday. KemPharm has a 1 year low of $2.45 and a 1 year high of $5.40. The company has a debt-to-equity ratio of -1.92, a quick ratio of 7.56 and a current ratio of 7.56. The stock has a market capitalization of $57.20 and a PE ratio of -1.30.

In related news, EVP Daniel L. Cohen bought 7,500 shares of the firm’s stock in a transaction dated Monday, November 27th. The stock was bought at an average price of $3.79 per share, with a total value of $28,425.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.80% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “KemPharm (KMPH) Receiving Somewhat Favorable News Coverage, Analysis Shows” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/25/kempharm-kmph-receiving-somewhat-favorable-news-coverage-analysis-shows.html.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Insider Buying and Selling by Quarter for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit